The Cardiac Effects of Prolonged Hypothermia After Cardiac Arrest

NCT ID: NCT02066753

Last Updated: 2015-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This PhD study is a sub study in a randomized clinical controlled multicenter trial named "TTH48" (ClinicalTrials.gov Identifier: NCT01689077).

The TTH48 trial examines prolonged mild therapeutic hypothermia ("MTH") at 32-34°C in 24 versus 48 hours with the primary outcome Cerebral Performance Category after 6 month in comatose out-of-hospital cardiac arrest patients.

THE OVERALL AIM OF THIS PhD STUDY IS TO INVESTIGATE THE CARDIAC FUNCTION AND THE HEMODYNAMICS BY BIOCHEMICAL CARDIAC MARKERS, ECHOCARDIOGRAPHY, BY ANALYZING THE USAGE OF INOTROPES/VASOPRESSORS AND BY ANALYZING ECG DATA FOR ARRHYTHMIAS IN THE 24 VERSUS 48 HOURS MTH GROUPS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PhD-study contains 3 sub studies:

* Study 1 estimates the extend of myocardial damage resulting from the primary arrest and from the reperfusion injuries: Area under the curve of cTnT and CK-MB as 12 repeated measurements and NT-proBNP as 4 measurements post arrest

-Hypothesis: There is a statistically significantly greater release of the cardiac biomarkers cTnT and NT-proBNP quantified by the area under the curve in the 24 versus the 48 hours group in the intervention period from 24 to 72 hours.
* Study 2 investigates MTH´s influence on systolic and diastolic function by standard and Tissue Doppler (TDI) echocardiography after 24, 48 and 72 hours. The primary endpoint is mitral annular systolic velocity ("S´ max")

-Primary hypothesis: There is statistically significant improvement in S' max from the time T24 to T72 in the 48 versus the 24 hours group.

-Secondary hypothesis: There is statistically significantly better systolic function at T48 measured in terms of individual S' max-change in the 48 hours group (still hypothermic) versus the 24 hours group (reached normothermia).
* Study 3 investigates MTH´s influence on the need for vasopressor or inotrope and the duration of arrhythmias during the first 72 hours post arrest.

* Primary hypothesis: There is a statistically significantly increased tendency of arrhythmias in the 48 versus the 24 hours group measured in the period from T0 to T72.
* Secondary hypothesis: There is a statistically significantly reduced need for inotropes in the 48 versus the 24 hours group measured by cumulative vasopressor index in the period from T0 to T72.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrest Hypothermia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

24 hours mild therapeutic hypothermia

The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.

Group Type ACTIVE_COMPARATOR

Mild therapeutic hypothermia

Intervention Type PROCEDURE

Mild therapeutic hypothermia with a target temperature between 32-34°C.

48 hours mild therapeutic hypothermia

The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.

Group Type EXPERIMENTAL

Mild therapeutic hypothermia

Intervention Type PROCEDURE

Mild therapeutic hypothermia with a target temperature between 32-34°C.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mild therapeutic hypothermia

Mild therapeutic hypothermia with a target temperature between 32-34°C.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Resuscitated after cardiac arrest outside hospital with suspected cardiac triggering cause (and stabile circulation for at least 20 minutes after return of spontaneous circulation,
2. Glasgow coma score \< 8 and
3. Age ≥ 18 years and \< 80 years.

Exclusion Criteria

1. Cardiac arrest of suspected non-cardiac triggering cause (e.g. trauma, aortic dissection, massive bleeding, hypoxia or accidental hypothermia),
2. \>60 minutes from cardiac arrest to ROSC,
3. Time from cardiac arrest until start of cooling \>4 hours,
4. Terminal illness,
5. Coagulopathy (medical anticoagulation treatment including thrombolysis is not a contraindication),
6. Unwitnessed arrests with asystolia as presenting rhythm,
7. Pregnancy,
8. Persistent cardiogenic shock,
9. Systolic blood pressure \<80 mmHg despite vasoactive treatment and intra-aortic balloon pump
10. CPC 3-4 before the cardiac arrest,
11. Suspected/confirmed acute intra cerebral hemorrhage or stroke,
12. Acute CABG or other operation in connection with performing CPR,
13. Lack of consent from the relatives,
14. Lack of consent from the GP and
15. Lack of consent from the patient if he/she wakes up and is relevant.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anders Grejs, MD

Role: PRINCIPAL_INVESTIGATOR

Research Center of Emergency Medicine and Department of Anesthesiology and Intensive Care Medicine, Aarhus University Hospital, Skejby, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Anesthesiology and Intensive Care Medicine, Aarhus University Hospital, Skejby

Aarhus N, Central Jutland, Denmark

Site Status

Research Center of Emergency Medicine and Department of Anesthesiology and Intensive Care Medicine, Stavanger University Hospital

Stavanger, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark Norway

References

Explore related publications, articles, or registry entries linked to this study.

Jensen TH, Juhl-Olsen P, Nielsen BRR, Heiberg J, Duez CHV, Jeppesen AN, Frederiksen CA, Kirkegaard H, Grejs AM. Echocardiographic parameters during prolonged targeted temperature Management in out-of-hospital Cardiac Arrest Survivors to predict neurological outcome - a post-hoc analysis of the TTH48 trial. Scand J Trauma Resusc Emerg Med. 2021 Feb 19;29(1):37. doi: 10.1186/s13049-021-00849-7.

Reference Type DERIVED
PMID: 33608045 (View on PubMed)

Grejs AM, Nielsen BRR, Juhl-Olsen P, Gjedsted J, Sloth E, Heiberg J, Frederiksen CA, Jeppesen AN, Duez CHV, Hamre PD, Soreide E, Kirkegaard H. Effect of prolonged targeted temperature management on left ventricular myocardial function after out-of-hospital cardiac arrest - A randomised, controlled trial. Resuscitation. 2017 Jun;115:23-31. doi: 10.1016/j.resuscitation.2017.03.021. Epub 2017 Apr 2.

Reference Type DERIVED
PMID: 28377297 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TTH48AG

Identifier Type: -

Identifier Source: org_study_id